Masafumi Koshiyama, MD, PhD

Professor
Department of Womens Health
Graduate school of human nursing
The university of Shiga Prefecture
522-8533, Japan

 

Biography

EDUCATIONAL QUALIFICATION AND PROFESSIONAL EXPERIENCES

• (1986) Graduated from Yamanashi University School of Medicine
• (1986-1987) Resident in Ob/Gy, Kyoto University Hospital
• (1987-1990 ) Medical Staff in Ob/Gy, Nagahama Red-Cross Hospital, Shiga
• (1990-1991 )Medical Staff in Ob/Gy, Toyooka Hospital, Hyogo
• (1991-1994) Medical Staff in Ob/Gy, Kyoto University Hospital
• (1995-2000) Medical Staff in Ob/Gy,Tenri Hospital, Nara
• (2000-2001) Medical Staff in Ob/Gy, Osaka National Hospital, Osaka
• (2001-2008) Director in Ob/Gy, Himeji national Hospital, Hyogo
• (2008-2013) Director in Ob/Gy, Otsu Red-Cross Hospital, Shiga
• (2013-Present) Assistant Professor in Ob/Gy, Kyoto University, Graduate School of Medicine

Research Interest

His research interest includes: Gynecologic pathology, Endometrial and ovarian carcinogenesis, Diagnosis and treatment for gynecologic cancers and Prevention of gynecologic cancers.

Scientific Activities

MEMBERSHIPS

• Japan Society of Obstetrics and Gynecology, Specialist
• Japan Society of Gynecologic Oncology, Specialist
• Japanese Board of Cancer Therapy, Specialist
• Japan Society of Clinical Oncology
• Japanese Cancer Association
• Japan Society of Perinatal and Neonatal Medicine
• Japan Clinical Oncology Group
• Japanese Gynecologic Oncology Group

Publications

1. Wang DP, Konishi I, Koshiyama M, et al. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. VirchowsArchiv A Pathological Anatomy and Histopathology. 1992; 421: 393-400
2. Kawakami S, Togashi K, Kimura I, et al . Primary malignant tumor of the fallopian tube: Appearance at CT and MR imaging. Radiology. 1993; 186: 503-508
3. Koshiyama M, Konishi I, Wang DP, et al. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. Virchows Archiv A Pathological Anatomy and Histopathology. 1993; 423: 265-271
4. Wang DP, Konishi I, Koshiyama M, et al. Expression of c-erbB-2 protein and epidermal growth factor receptor in endometrial carcinomas. Cancer. 1993; 72, 2628-2637
5. Koshiyama M, Konishi I, Yoshida M, et al. Transitional cell carcinoma of the fallopian tube: A light and electron microscopic study. International Journal of Gynecological Pathology. 1994; 13:175-180
6. Konishi I, Ishikawa Y, Wang SY, et al. Expression of transforming growth factor-α in the normal cervix and in benign and malignant lesions of the uterine cervix. British Journal of Obstetrics and Gynaecology. 1994; 101: 325-329.
7. Mandai M, Konishi I, Koshiyama M, et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: Correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Research. 1994; 54: 1825-1830
8. Koshiyama M, Konishi I, Mandai M, et al. Immunohistochemical analysis of p53 protein and 72 kDa heat shockprotein (HSP72) expression in ovarian carcinomas: Correlation with clinicopathology and sex steroid receptor status. Virchows Archiv. 1995; 425: 603-609
9. Komatsu T, Konishi I, Mandai M, et al. Peritoneal papillary serous carcinoma arising in an infertile woman during ovulation-induction therapy: Immunohistochemical expression of LH/hCG receptors. Gynecologic Oncology. 1995; 56: 470-474
10. Koshiyama M, Konishi I, Nanbu K, et al. Immunohistochemical localization of heat shock proteins HSP70 and HSP90 in the human endometrium: Correlation with sex steroid receptors and Ki-67 antigen expression. Journal of Clinical Endocrinology and Metabolism. 1995; 80: 1106-1112.
11. Mandai M, Konishi I, Koshiyama M, et al. Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer. 1995; 75, 2523-2529
12. Nanbu K, Konishi I, Yamamoto S, Koshiyama M, et al. Minimal deviation adenocarcinoma of endometrioid type may arise in the isthmus: Clinicopathological and immunohistochemical study of two cases. Gynecologic Oncology. 1995; 58, 136-141.
13. Konishi I, Koshiyama M, Mandai M, et al. Sex steroid receptors, LH/hCG receptor, and oncogene expression in endometrial carcinomas. Recent Developments in Gynecology and Obstetrics. The Parthenon Publishing Group, New York & London. 1995; 715-719
14. Mandai M, Konishi I, Koshiyama M, et al. Ascitic positive cytology and intraperitoneal metastasis in ovarian dysgerminoma. The Journal of Obstetrics and Gynaecology Research. 1996; 22: 89-94
15. Nanbu K, Konishi I, Komatsu T, et al. Expression of heat shock proteins HSP70 and HSP90 in endometrialcarcinomas: Correlation with clinicopathology,sex steroid receptor status, and p53 proteinexpresssion. Cancer. 1996; 77: 330-338
16. Koshiyama M, Yoshida M, Takemura M, et al. YImmunohistochemical analysis of distribution of estrogen receptors and progesterone receptors in the postmenopausal endometrium. Acta Obstetriciaet GynecologicaS candinavica. 1996; 75: 702-706. doi: 10.3109/00016349609065730
17. Yura Y, Tauchi K,Koshiyama M, et al. Parametrial involvement in endometrial carcinomas: Its incidence and correlation with other histological parameters. Gynecologic Oncology. 1996; 63: 114-119.
18. Komatsu T, Konishi I, Fukumoto M, et al. Messenger ribonucleic acid expression of heat shock proteins HSP70 and HSP90 in human endometrium and myometrium during the menstrual cycle. Journal of Clinical Endocrinology and Metabolism. 1997; 82: 1385-1389
19. Koshiyama M, Yoshida M, Konishi M, et al. Expression of pS2 protein in endometrial carcinomas: Correlation with clinicopathlogicfeatures and sex steroid receptor status. International Journal of Cancer (Pred. Oncol) . 1997; 74: 237-244
20. Konishi I, Koshiyama M, Mandai M, et al. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women. Gynecologic Oncology. 1997; 65: 273-280.
21. Koshiyama M, Yoshida M, Takemura M, et al. Management of malignant ovarian tumors in young women: 21 nulliparous cases. Gynecologicand Obstetric Investigation. 1998; 45, 132-136
22. Yoshida M,Koshiyama M,Konishi M, et al. Ovarian dysgerminoma showing high serum levels and positive immunostaining of placentalalkaline phosphatase and neuron-specific enolase associated with elevation of serum prolactin level. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1998; 81, 123-128
23. Koshiyama M, Konishi I, Fujii S. Pathology, hormonal aspects, and molecular genetics of the two types of endometrial cancer [Review]. The Cancer Journal. 1998; 11, 277-283 24. Koshiyama M, Fujii H, Konishi M, et al. Recurrent clear cell carcinoma of the ovary changing into producing parathyroid hormone-related protein (PTH-rP) with hypercalcemia. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1999; 82, 227-229
25. Koshiyama M, Yoshida M, Fujii H, et al. Expression of multidrug resistance-associated protein in endometrial carcinomas: Correlation with clinicopathology and prognosis. Annals of Diagnostic Pathology. 1999; 3: 81-87.
26. Yoshida M, Koshiyama M, Fujii H, et al. Erythrocytosis and a fibroid. Lancet. 1999; 354: 216.
27. Koshiyama M, Yoshida M, Fujii H, et al. Ovarian actinomycosis complicated by diabetes mellitus simulating an advanced ovarian carcinoma. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1999; 87: 95-99.
28. Koshiyama M, Fujii H, Kinezaki M, et al. Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas : a comparison against cisplatin. Anticancer Research. 2000; 20, 1353-1358
29. Koshiyama M, Morita Y, Fujii H, et al. Gynecologic malignancies accompanied by benign hormone-dependent disease. Menopause. 2001; 8: 149-150
30. Koshiyama M, Fujii H, Kinezaki M, et al. Correlation between Topo II α expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Anticancer Research. 2001; 21: 905-910
31. Koshiyama M, Fujii H, Kinezaki M, et al. Immunohistochemical expression of Topoisomerase II α(Topo II α) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Research. 2001; 21. 2925-2932
32. Fujii H,Koshiyama M, Konishi M, et al. Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effect. Cancer Detection and Prevention. 2002; 26. 210-212
33. Koshiyama M, Suzuki A, Ozawa M, et al. Adenocarcinomas arising from adenomyosis uteri: A report of four cases. International Journal of Gynecological Pathology. 2002; 21. 239-245
34. Koshiyama M, Ueta M. Two kinds of endometrial neoplasia arising from different origins in the uterine corpus. Comparison of p53 expression and sex steroid receptor status. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2002; 104: 167-170
35. Kaji Y, Matsuo M, Matsuki M, et al. Cystic ocarian lesions in SSFP diffusion imaging. Magnetic Resonance in Medical Sciences. 2002; 1: 183-189
36. Okamoto T, Koshiyama M, Yamamoto K. Treatment of huge uterine tumors thought to be benign in post-menopausalwomen. Medical Science Monitor. 2004; 10: CR43-CR45 37. Koshiyama M, Ueta M, Okamoto T, et al. Mulerianadenosarcoma arising from the uterine cervix. Acta Obstetriciaet Gynecologica Scandinavica. 2004; 83:315-316.
38. Koshiyama M, Okamoto T, Ueta M. The relationship between endometrial carcinoma and coexistent adenomyosis uteri, endometriosis externa and myoma uteri. Cancer Detection and Prevention. 2004; 28: 94-98
39. Okamoto T, Koshiyama M, Yamamoto K Rapidly growing leiomyoma in a postmenopausal woman. The Journal of Obstetrics and Gynaecology Research. 2004; 30: 316-318
40. Koshiyama M, Kinezaki M, Uchida T, et al. Chemosensivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin. Anticancer Research. 2005; 25: 4499-4502.
41. Koshiyama M, Kinezaki M, Uchida T, et al. Chemosensivity testing of paclitaxel versus docetaxel in human gynecological carcinomas, Comparisons with a carboplatin. Anticancer Research. 2006; 26: 3655-3660.
42. Ukita S, Koshiyama M, Ohnaka M, et al. Retroperitoneal lipoma arising from the urinary bladder. Rare Tumors. 2009; 1: e34-e35
43. Okamoto T, Matsumura N, Mandai M, et al. Distinguishing primary from secondary mucinous ovarian tumors: an algorithm using the novel marker DPEP1. Modern Pathology. 2011; 24: 267-276 doi: 10.1038/modpathol.2010.204.
44. Ukita S, Koshiyama M, Yamaguchi A, et al. Total uterine rupture during pregnancy after an adenomyomectomy. The American Journal of Case Reports. 2011; 12: 106-109 doi: 10.12659/AJCR.881914
45. Yamanishi Y, Koshiyama M, Ohnaka M, et al. Pathways of metastases from primary organs to the ovaries. Obstetrics and Gynecology International. 2011; ID 612817, 1-6 doi: 10.1155/2011/612817
46. Ueda M, Koshiyama M, Yamaguchi A, et al. Advanced papillary serous carcinoma of the uterine cervix: a case with a remarkable response to paclitaxel and carboplatin combinationchemotherapy. Rare Tumors. 2012; 4: e1-e3 doi: 10.4081/rt.2012.e1
47. Hishikawa K, Koshiyama M, Ueda M, et al. Exchange of intraoperative balloon occlusion of the internal iliac artery for the common iliac artery during cesarean hysterectomy in a patient with placenta percreta: a case report. The American Journal of Case Reports. 2013; 14: 409-411 doi: 10.12659/AJCR.889449.
48. Koshiyama M, Matsumura N, Baba T, et al. Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. Cancer Biology & Therapy. 2014; 15: 22-25 doi: 10.4161/cbt.26608.
49. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type I and Type II. review. BioMed Research International. 2014; 934261: 1-11 doi: 10.1155/2014/934261
50. Baba T, Kang HS, Hosoe Y, et al. Menstrual cyclic change of metastin/GPR54 in endometrium. Med Mol Morphol. 2014; 1-9. doi: 10.1007/s00795-014-0081-0
51. Nagura M, Koshiyama M, Matsumura N, et al. Clinical approaches to treating papillary squamous cell carcinoma of the uterine cervix. BMC Cancer. 2014; 14: 1-7 doi: 10.1186/1471-2407-14-784
52. Nagura M, Matsumura N, Baba T, et al. Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta. Gynecol Oncol. 2014; 136: 104-111 doi: 10.1016/j.ygyno.2014.11.075.
53. Ueda M, Moshiyama M, Sato Y. Prophylactic corticosteroids in pulmonary oil embolism after hysterosalpingography. J Obstetrics Gynecology early online. 2015; 1-2 doi: 10.3109/01443615.2015.1041892
54. Horikawa N, Baba T, Matsumura N, et al. Genomic profile predicts the efficacy of neoadjuvant chemotherapy forcervical cancer patients. BMC Cancer. 2015; 15: 2-9.